Home > Insider Trading > Filing (0001181431-12-025889)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1133416	Galectin Therapeutics Inc	GALT	Pharmaceutical Preparations (2834)	043562325

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1522480	F John Mauldin	C/O Galectin Theraputics Inc. 7 Wells Avenue, Suite 34 Newton MA 02459		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-04-24	3,847	$2.94	3,847	No	4	P	Indirect	By trust
Common Stock	Acquisiton	2012-04-25	1,100	$3.08	4,947	No	4	P	Indirect	By Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By trust
No	4	P	Indirect	By Trust

Footnotes

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.94 to $2.97 inclusive. The reporting person undertakes to provide Galectin Therapeutics Inc., any security holder of Galectin Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.97 to $3.08 inclusive. The reporting person undertakes to provide Galectin Therapeutics Inc., any security holder of Galectin Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
On the transaction date stated in column 2 of this row in Table I, the reporting person contributed the shares stated in column 4 of such row to a retirement fund trust of which the reporting person is a trustee and a beneficiary. The reporting person continues to report ownership of all Galectin Therapeutics common stock held by the trust but disclaims beneficial ownership except to the extent of his pecuniary interest therein.